Drug or technology
3 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
This is a Phase 2 platform trial registration with no results reported; it describes a planned interventional study in early-stage disease with a surrogate endpoint (tau PET), appropriate for preliminary classification.
AUG 6, 2026 · PHASE 2 TRIAL
ClinicalTrials.gov
This is a Phase 2 clinical trial registry record with no reported results; it describes a planned study design and enrollment target only.
AUG 6, 2026 · PHASE 3 TRIAL
ClinicalTrials.gov
This is an active Phase 3 trial registration with no results reported; donanemab's efficacy and safety in Chinese preclinical AD remain unevaluated pending completion.